Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial
David N. Krag,Stewart J. Anderson,Thomas B. Julian,Ann M. Brown,Seth P. Harlow,Joseph P. Costantino,Takamaru Ashikaga,Donald L. Weaver,Eleftherios P. Mamounas,Lynne M. Jalovec,Thomas G. Frazier,R. Dirk Noyes,André Robidoux,Hugh M.C. Scarth,Norman Wolmark +14 more
TLDR
Overall survival, disease-free survival, and regional control were statistically equivalent between groups, and outcome analyses were done in patients who were assessed as having pathologically negative sentinel nodes and for whom follow-up data were available.Abstract:
Summary Background Sentinel-lymph-node (SLN) surgery was designed to minimise the side-effects of lymph-node surgery but still offer outcomes equivalent to axillary-lymph-node dissection (ALND). The aims of National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-32 were to establish whether SLN resection in patients with breast cancer achieves the same survival and regional control as ALND, but with fewer side-effects. Methods NSABP B-32 was a randomised controlled phase 3 trial done at 80 centres in Canada and the USA between May 1, 1999, and Feb 29, 2004. Women with invasive breast cancer were randomly assigned to either SLN resection plus ALND (group 1) or to SLN resection alone with ALND only if the SLNs were positive (group 2). Random assignment was done at the NSABP Biostatistical Center (Pittsburgh, PA, USA) with a biased coin minimisation approach in an allocation ratio of 1:1. Stratification variables were age at entry (≤49 years, ≥50 years), clinical tumour size (≤2·0 cm, 2·1–4·0 cm, ≥4·1 cm), and surgical plan (lumpectomy, mastectomy). SLN resection was done with a blue dye and radioactive tracer. Outcome analyses were done in patients who were assessed as having pathologically negative sentinel nodes and for whom follow-up data were available. The primary endpoint was overall survival. Analyses were done on an intention-to-treat basis. All deaths, irrespective of cause, were included. The mean time on study for the SLN-negative patients with follow-up information was 95·6 months (range 70·1–126·7). This study is registered with ClinicalTrials.gov, number NCT00003830. Findings 5611 women were randomly assigned to the treatment groups, 3989 had pathologically negative SLN. 309 deaths were reported in the 3986 SLN-negative patients with follow-up information: 140 of 1975 patients in group 1 and 169 of 2011 in group 2. Log-rank comparison of overall survival in groups 1 and 2 yielded an unadjusted hazard ratio (HR) of 1·20 (95% CI 0·96–1·50; p=0·12). 8-year Kaplan-Meier estimates for overall survival were 91·8% (95% CI 90·4–93·3) in group 1 and 90·3% (88·8–91·8) in group 2. Treatment comparisons for disease-free survival yielded an unadjusted HR of 1·05 (95% CI 0·90–1·22; p=0·54). 8-year Kaplan-Meier estimates for disease-free survival were 82·4% (80·5–84·4) in group 1 and 81·5% (79·6–83·4) in group 2. There were eight regional-node recurrences as first events in group 1 and 14 in group 2 (p=0·22). Patients are continuing follow-up for longer-term assessment of survival and regional control. The most common adverse events were allergic reactions, mostly related to the administration of the blue dye. Interpretation Overall survival, disease-free survival, and regional control were statistically equivalent between groups. When the SLN is negative, SLN surgery alone with no further ALND is an appropriate, safe, and effective therapy for breast cancer patients with clinically negative lymph nodes. Funding US Public Health Service, National Cancer Institute, and Department of Health and Human Services.read more
Citations
More filters
Journal ArticleDOI
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
TL;DR: Broad treatment recommendations are presented, recognizing that detailed treatment decisions need to consider disease extent, host factors, patient preferences, and social and economic constraints.
Journal ArticleDOI
Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial
Armando E. Giuliano,Kelly K. Hunt,Karla V. Ballman,Peter D. Beitsch,Pat Whitworth,Peter W. Blumencranz,A. Marilyn Leitch,Sukamal Saha,Linda M. McCall,Monica Morrow +9 more
TL;DR: Among patients with limited SLN metastatic breast cancer treated with breast conservation and systemic therapy, the use of SLND alone compared with ALND did not result in inferior survival, and overall survival was the primary end point, with a noninferiority margin of a 1-sided hazard ratio of less than 1.3 indicating thatSLND alone is noninherited.
Journal ArticleDOI
Breast Cancer Treatment: A Review.
Adrienne G. Waks,Eric P. Winer +1 more
TL;DR: This review focuses on current approaches and evolving strategies for local and systemic therapy of breast cancer as well as distinct risk profiles and treatment strategies.
Journal ArticleDOI
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Elżbieta Senkus,Stella Kyriakides,Frédérique Penault-Llorca,P.M. Poortmans,Alexander J. Thompson,Sophia Zackrisson,Fatima Cardoso +6 more
TL;DR: This work presents the results of a meta-analysis conducted at the 2016 European Oncology and Radiotherapy Guidelines Working Group (ESMO) workshop on breast cancer diagnosis and prognosis of women with atypical central giant cell granuloma (CGM) who have previously had surgery.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
TL;DR: Lymphedema is a common complication after treatment for breast cancer and factors associated with increased risk of lymphedEMA include extent of axillary surgery, axillary radiation, infection, and patient obesity.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Regression models and life tables (with discussion
TL;DR: The drum mallets disclosed in this article are adjustable, by the percussion player, as to balance, overall weight, head characteristics and tone production of the mallet, whereby the adjustment can be readily obtained.
Journal ArticleDOI
Proportional hazards tests and diagnostics based on weighted residuals
TL;DR: In this article, Chen et al. showed that a treatment effect that decreases with time can be directly visualized by smoothing an appropriate residual plot, which can be expressed as a weighted least-squares line fitted to the residual plot.
Journal ArticleDOI
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
TL;DR: In this paper, a class of tests developed for comparing the cumulative incidence of a particular type of failure among different groups is presented. The tests are based on comparing weighted averages of the hazards of the subdistribution for the failure type of interest.
Journal ArticleDOI
Five-Year Results of a Randomized Clinical Trial Comparing Total Mastectomy and Segmental Mastectomy with or without Radiation in the Treatment of Breast Cancer
Bernard Fisher,M Bauer,Richard G. Margolese,Roger Poisson,Yosef Pilch,Carol K. Redmond,Edwin R. Fisher,Norman Wolmark,Melvin Deutsch,E Montague +9 more
TL;DR: It is concluded that segmental mastectomy, followed by breast irradiation in all patients and adjuvant chemotherapy in women with positive nodes, is appropriate therapy for Stage I and II breast tumors less than or equal to 4 cm, provided that margins of resected specimens are free of tumor.
Related Papers (5)
Randomized Multicenter Trial of Sentinel Node Biopsy Versus Standard Axillary Treatment in Operable Breast Cancer: The ALMANAC Trial
Robert E. Mansel,Lesley Fallowfield,Mark Kissin,Amit Goyal,Robert G. Newcombe,J Michael Dixon,Constantinos Yiangou,Kieran Horgan,Nigel J Bundred,I. Monypenny,David England,Mark Sibbering,Tholkifl I. Abdullah,Lester Barr,Utheshtra Chetty,Dudley H. Sinnett,Anne Fleissig,Dayalan Clarke,Peter J. Ell +18 more
Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial
M. Donker,Geertjan van Tienhoven,Marieke E. Straver,P. Meijnen,Cornelis J.H. van de Velde,Robert E. Mansel,Luigi Cataliotti,A. Helen Westenberg,Jean H. G. Klinkenbijl,Lorenzo Orzalesi,Willem H. Bouma,Huub van der Mijle,Grard A. P. Nieuwenhuijzen,Sanne C. Veltkamp,Leen Slaets,Nicole Duez,Peter W. de Graaf,Thijs van Dalen,A. Marinelli,Herman Rijna,Marko Snoj,Nigel J Bundred,Jos W. S. Merkus,Yazid Belkacemi,Patrick Petignat,Dominic A.X. Schinagl,Corneel Coens,Carlo Messina,Jan Bogaerts,Emiel J. Th. Rutgers +29 more